144 related articles for article (PubMed ID: 35443604)
21. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant
Brodská B; Otevřelová P; Šálek C; Fuchs O; Gašová Z; Kuželová K
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185600
[TBL] [Abstract][Full Text] [Related]
22. [Expression and Clinical Significance of PD-L1 and MicroRNA-138-5p in Patients with Acute Myeloid Leukemia].
Huang CY; Zha XF; Wen WR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):373-378. PubMed ID: 30998140
[TBL] [Abstract][Full Text] [Related]
23. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
Zhang L; Gajewski TF; Kline J
Blood; 2009 Aug; 114(8):1545-52. PubMed ID: 19417208
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
25. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Sehgal A; Whiteside TL; Boyiadzis M
Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
[TBL] [Abstract][Full Text] [Related]
26. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
[TBL] [Abstract][Full Text] [Related]
27. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
28. B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.
Antohe I; Dǎscǎlescu A; Dǎnǎilǎ C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Pavel M; Cianga P
Front Oncol; 2020; 10():264. PubMed ID: 32231996
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
30. Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?
Korkmaz S; Erdem S; Akay E; Taşdemir EA; Karaman H; Keklik M
Turk J Med Sci; 2019 Feb; 49(1):265-271. PubMed ID: 30761875
[TBL] [Abstract][Full Text] [Related]
31. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
Zhou Q; Munger ME; Highfill SL; Tolar J; Weigel BJ; Riddle M; Sharpe AH; Vallera DA; Azuma M; Levine BL; June CH; Murphy WJ; Munn DH; Blazar BR
Blood; 2010 Oct; 116(14):2484-93. PubMed ID: 20570856
[TBL] [Abstract][Full Text] [Related]
32. [Expression and Significance of PD-L1, HSP90 and HSP90α in Serum of Patients with Acute Leukemia].
Ma XJ; Zhang FH; Sun L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1384-1389. PubMed ID: 29070112
[TBL] [Abstract][Full Text] [Related]
33. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
34. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
van Ens D; Mousset CM; Hutten TJA; van der Waart AB; Campillo-Davo D; van der Heijden S; Vodegel D; Fredrix H; Woestenenk R; Parga-Vidal L; Jansen JH; Schaap NPM; Lion E; Dolstra H; Hobo W
Bone Marrow Transplant; 2020 Dec; 55(12):2308-2318. PubMed ID: 32528120
[TBL] [Abstract][Full Text] [Related]
36. Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.
Tracy SI; Venkatesh H; Hekim C; Heltemes-Harris LM; Knutson TP; Bachanova V; Farrar MA
Blood; 2022 Jul; 140(4):335-348. PubMed ID: 35275990
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
38. Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.
Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
Eur J Haematol; 2016 Dec; 97(6):517-527. PubMed ID: 27096305
[TBL] [Abstract][Full Text] [Related]
39. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
40. [Relationship of PD-L1 Expression with the Clinical Features and Prognosis of Patients with Primary Acute Leukemia].
Ma H; Li N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1034-8. PubMed ID: 27531770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
